Adaptimmune Therapeutics plc

(NASDAQ:ADAP)

Latest On Adaptimmune Therapeutics plc (ADAP):

Date/Time Type Description Signal Details
2023-05-12 19:12 ESTNewsAdaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6MN/A
2023-05-12 19:11 ESTNewsAdaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 15:07 ESTNewsAdaptimmune Q1 2023 Earnings PreviewN/A
2023-04-21 16:43 ESTNewsAdaptimmune Shareholders Can Lock In A Big Merger Spread By Swapping To TCR2 TherapeuticsN/A
2023-04-18 19:19 ESTNewsAdaptimmune, TCR2 Therapeutics set May 30 for shareholder votes on dealN/A
2023-04-11 23:15 ESTNewsAdaptimmune to regain rights to cancer drug programs from GSKN/A
2023-03-26 19:28 ESTNewsAdaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic InvestorsN/A
2023-03-07 00:03 ESTNewsAdaptimmune Therapeutics plc (ADAP) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 09:28 ESTNewsTCR² Therapeutics stock rise 41% after merger deal with AdaptimmuneN/A
2023-03-06 09:28 ESTNewsAdaptimmune GAAP EPS of -$0.03 beats by $0.20, revenue of $11.03M beats by $5.95MN/A
2023-03-06 09:28 ESTNewsAdaptimmune sheds nearly 26% after strategic combination with TCR² Therapeutics; tops Q4 consensusN/A
2023-03-03 16:59 ESTNewsAdaptimmune Q4 2022 Earnings PreviewN/A
2023-01-04 01:12 ESTNewsAdaptimmune stock soars ~15% as Guggenheim upgrades rating to BuyN/A
2022-12-10 05:26 ESTNewsAdaptimmune: The Afamicel Rolling BLA Is Its LifelineN/A
2022-11-09 18:40 ESTNewsAdaptimmune Therapeutics upgraded at Mizuho on clarity for afami-celN/A
2022-11-09 00:46 ESTNewsAdaptimmune stock rises as drug shows promise across cancer types in phase 1 trialN/A
2022-11-09 00:46 ESTNewsAdaptimmune GAAP EPS of -$0.04 beats by $0.22, revenue of $7M beats by $2.03MN/A
2022-11-09 00:46 ESTNewsAdaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Call TranscriptN/A
2022-11-07 13:21 ESTNewsAdaptimmune Q3 2022 Earnings PreviewN/A
2022-10-25 21:16 ESTNewsGSK to transfer back cancer drug programs to AdaptimmuneN/A
2022-09-20 10:43 ESTNewsAdaptimmune Therapeutics: Depressed Despite Upcoming BLAN/A
2022-09-16 04:09 ESTNewsAdaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - SlideshowN/A
2022-09-09 16:41 ESTNewsAdaptimmune updates early-stage data for solid tumor candidateN/A
2022-08-07 18:17 ESTNewsAdaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 22:04 ESTNewsAdaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16MN/A
2022-08-03 15:56 ESTNewsAdaptimmune Q2 2022 Earnings PreviewN/A
2022-08-03 15:56 ESTNewsGene editing companies benefitting from Roche deal with CAR-T player Poseida TherapeuticsN/A
2022-06-29 10:03 ESTNewsAdaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022N/A
2022-06-19 12:03 ESTNewsFinally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLAN/A
2022-05-16 07:00 ESTNewsAdaptimmune Therapeutics plc 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 00:19 ESTNewsAdaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4MN/A
2022-05-10 00:19 ESTNewsAdaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-20 23:42 ESTNewsAdaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%N/A
2022-04-09 02:18 ESTNewsAdaptimmune files for $400M mixed shelf offering; shares down 5% after hoursN/A
2022-04-09 02:18 ESTNewsAdaptimmune Therapeutics drops 5% on $400 mixed shelf offeringN/A
2022-03-14 22:04 ESTNewsAdaptimmune GAAP EPS of -$0.04, revenue of $1.4MN/A
2022-03-14 22:04 ESTNewsAdaptimmune Therapeutics Plc's (ADAP) CEO Adrian Rawcliffe On Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-06 21:45 ESTNewsAdaptimmune Therapeutics: A Little More Patience May Be ProfitableN/A
2021-12-15 03:56 ESTNewsCircling Back On Adaptimmune TherapeuticsN/A
2021-11-11 19:24 ESTNewsAdaptimmune says mid-stage trial for afami-cel in soft tissue cancer will meet main goalN/A
2021-11-04 23:03 ESTNewsAdaptimmune EPS beats by $0.21, beats on revenueN/A
2021-11-04 23:03 ESTNewsAdaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 01:45 ESTNewsAdaptimmune Q3 2021 Earnings PreviewN/A
2021-10-13 14:56 ESTNewsAs CRISPR continues to falter, other CAR-T names aren't impactedN/A
2021-09-30 06:55 ESTNewsAdaptimmune Therapeutics: Diverse Pipeline With Approval LoomingN/A
2021-09-22 17:52 ESTNewsAdaptimmune Therapeutics updates early-stage for solid tumor candidateN/A
2021-09-08 02:24 ESTNewsAdaptimmune, Genentech collaborate to develop cancer-targeted allogeneic t-cell therapiesN/A
2021-09-08 02:24 ESTNewsAdaptimmune surges 24% on Roche deal for allogeneic cell therapies for cancerN/A
2021-09-07 06:47 ESTNewsAdaptimmune updates data from Phase 1 trial for liver cancer at ILCAN/A
2021-08-28 17:03 ESTNewsStocks To Watch: Bright Lights On Li Auto, Lululemon, DocuSign And AutodeskN/A

About Adaptimmune Therapeutics plc (ADAP):

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Quotes by TradingView

See Advanced Chart

General

  • Name Adaptimmune Therapeutics plc
  • Symbol ADAP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 462
  • Fiscal Year EndDecember
  • IPO Date2015-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.adaptimmune.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 194.73
  • Price/Book (Most Recent Quarter) 2.46
  • Enterprise Value Revenue 125.01
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.00
  • Next Year EPS Estimate -$1.06
  • Next Quarter EPS Estimate -$0.25
  • Operating Margin -3371%
  • Return on Assets -26%
  • Return on Equity -56%
  • Revenue 3.96 million
  • Earnings Per Share -$0.97
  • Revenue Per Share $0.03
  • Gross Profit -87610000
  • Quarterly Earnings Growth 106.3%
View More

Highlights

  • Market Capitalization 806.72 million
  • EBITDA -86400000
  • PEG Ratio 0.11
  • Analyst Target Price $11.33
  • Book Value Per Share $2.20
View More

Share Statistics

  • Shares Outstanding 155.14 million
  • Shares Float 125.77 million
  • % Held by Insiders 22%
  • % Held by Institutions 84.05%
  • Shares Short 1.85 million
  • Shares Short Prior Month 1.51 million
  • Short Ratio 1.68
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.21
  • 52 Week High $12.48
  • 52 Week Low $2.5
  • 50 Day Moving Average 5.83
  • 200 Day Moving Average 6.09
View More

Dividends

  • Dividend Date 2018-03-30
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Adaptimmune Therapeutics plc (ADAP) Dividend Calendar:

ADAP's last dividend payment was made to shareholders on March 30, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Adaptimmune Therapeutics plc (ADAP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$1.5 million-$0.24-$0.23-2.87%
2020-09-302020-11-05$1.19 million-$0.24-$0.255.25%
2020-06-302020-08-06$N/A-$0.24-$0.24-1.39%
2020-03-312020-05-14$761000-$0.24-$0.255.25%
2019-12-312020-02-27$728000-$0.30-$0.3411.76%
2019-09-302019-11-06$237000-$0.36-$0.31-16.13%
2019-06-302019-08-01$157000-$0.42-$0.34-22.63%
2019-03-312019-05-06$N/A-$0.24-$0.266.98%
2018-12-312019-02-27$1.48 million-$0.36-$0.32-14.29%
2018-09-302018-11-06$40.79 million$0.06$0.26-76.92%
2018-06-302018-08-02$9.04 million-$0.48-$0.26-86.41%
2018-03-312018-05-09$8.2 million-$0.24-$0.24-1.39%
2017-12-312018-03-15$4.27 million-$0.30-$0.25-20%
2017-09-302017-11-02$27.19 million-$0.01-$0.1994.64%
2017-06-302017-08-03$3.52 million-$0.24-$0.20-22.45%
2017-03-312017-05-10$2.86 million-$0.30-$0.22-37.93%
2016-12-312017-03-13$8.54 million-$0.22-$0.3026.67%
2016-09-302016-11-10$2.42 million-$0.26-$0.286.31%
2016-06-302016-08-08$328000-$0.31-$0.19-65.33%
2016-03-312016-05-12$2.92 million-$0.22-$0.20-10%
2015-12-312016-03-17$4.18 million-$0.16-$0.14-14.29%
2015-09-302015-10-13$3.93 million-$0.02-$0.0771.43%

Adaptimmune Therapeutics plc (ADAP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Adaptimmune Therapeutics plc (ADAP) Chart:

Adaptimmune Therapeutics plc (ADAP) News:

Below you will find a list of latest news for Adaptimmune Therapeutics plc (ADAP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Adaptimmune Therapeutics plc (ADAP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-170.50CALL0 0417.83TRUE00
2024-05-1710.16CALL10 21128.55TRUE0.160
2024-05-171.50.03CALL0 1320FALSE00
2024-05-1720.05CALL0 100FALSE00
2024-05-172.50CALL0 00FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-170.50PUT0 00FALSE00
2024-05-1710.15PUT0 203131.57FALSE00
2024-05-171.50.45PUT0 240TRUE00
2024-05-1720PUT0 0251.3TRUE00
2024-05-172.51.35PUT0 0263.24TRUE00
2024-05-1750PUT0 0508.67TRUE00
2024-05-177.50PUT0 0644.33TRUE00
2024-06-210.50.51CALL0 24253.73TRUE00
2024-06-2110.24CALL4 78128.66TRUE-0.01-0.04
2024-06-211.50.05CALL6 118898.44FALSE-0.04-0.44
2024-06-2120.07CALL0 7560FALSE00
2024-06-212.50.05CALL8 1335170.19FALSE0.010.25
2024-06-2150.1CALL0 310FALSE00
2024-06-217.50.05CALL0 30FALSE00
2024-06-210.50PUT0 00FALSE00
2024-06-2110.14PUT20 120107.8FALSE0.020.17
2024-06-211.50.44PUT0 70177.3TRUE00
2024-06-2120.54PUT0 126158.98TRUE00
2024-06-212.51.3PUT0 166137.47TRUE00
2024-06-2154.1PUT0 0322.27TRUE00
2024-06-217.50PUT0 0268.64TRUE00
2024-09-200.50.6CALL0 536543.14TRUE00
2024-09-2010.4CALL0 1610132.8TRUE00
2024-09-201.50.25CALL0 1119137.59FALSE00
2024-09-2020.24CALL0 1285139.64FALSE00
2024-09-202.50.1CALL18 2317129.02FALSE-0.03-0.23
2024-09-2050.09CALL0 161204.22FALSE00
2024-09-207.50.15CALL0 830FALSE00
2024-09-200.50PUT0 00FALSE00
2024-09-2010.4PUT0 29201.81FALSE00
2024-09-201.50.75PUT0 11132.56TRUE00
2024-09-2021.15PUT0 82165.24TRUE00
2024-09-202.51.5PUT0 25169.03TRUE00
2024-09-2054.1PUT0 0233.9TRUE00
2024-09-207.50PUT0 0188.41TRUE00
2024-12-200.50.75CALL0 26182.88TRUE00
2024-12-2010.55CALL0 9206TRUE00
2024-12-201.50.35CALL10 21136.7FALSE-0.05-0.13
2024-12-2020.2CALL0 1260.48FALSE00
2024-12-202.50CALL0 00FALSE00
2024-12-2050CALL0 00FALSE00
2024-12-207.50CALL0 00FALSE00
2024-12-200.50PUT0 0135.24FALSE00
2024-12-2010PUT0 0133.98FALSE00
2024-12-201.50PUT0 0122.22TRUE00
2024-12-2021.2PUT0 5126.74TRUE00
2024-12-202.50PUT0 0153.24TRUE00
2024-12-2050PUT0 0157.51TRUE00
2024-12-207.50PUT0 0224.51TRUE00

Latest ADAP Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$1.525
Jun 13, 2022 7:58 PM EST4$1.525
Jun 13, 2022 7:58 PM EST100$1.525
Jun 13, 2022 7:59 PM EST100$1.525
Jun 13, 2022 7:59 PM EST100$1.525

Adaptimmune Therapeutics plc (ADAP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120039805/0001209191-20-039805-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621227/000090266420001127/0000902664-20-001127-index.htm
2020-01-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621227/000104746920000356/0001047469-20-000356-index.htm
2020-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621227/000104746920000402/0001047469-20-000402-index.htm
2020-06-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621227/000104746920003280/0001047469-20-003280-index.htm
2020-06-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1621227/000104746920003304/0001047469-20-003304-index.htm
2019-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465919067634/0001104659-19-067634-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920002080/0001104659-20-002080-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920002081/0001104659-20-002081-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920002082/0001104659-20-002082-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920003216/0001104659-20-003216-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920003256/0001104659-20-003256-index.htm
2020-01-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920003552/0001104659-20-003552-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920003597/0001104659-20-003597-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004419/0001104659-20-004419-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004420/0001104659-20-004420-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004421/0001104659-20-004421-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004422/0001104659-20-004422-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004423/0001104659-20-004423-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920004424/0001104659-20-004424-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005256/0001104659-20-005256-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005258/0001104659-20-005258-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005261/0001104659-20-005261-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005262/0001104659-20-005262-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005263/0001104659-20-005263-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920005985/0001104659-20-005985-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920012543/0001104659-20-012543-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920022267/0001104659-20-022267-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920025722/0001104659-20-025722-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920042011/0001104659-20-042011-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920042012/0001104659-20-042012-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920042013/0001104659-20-042013-index.htm
2020-04-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920044488/0001104659-20-044488-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920044489/0001104659-20-044489-index.htm
2020-04-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920048476/0001104659-20-048476-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920051986/0001104659-20-051986-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920052846/0001104659-20-052846-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920059925/0001104659-20-059925-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920061166/0001104659-20-061166-index.htm
2020-05-2810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621227/000110465920067101/0001104659-20-067101-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920067340/0001104659-20-067340-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920067350/0001104659-20-067350-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920069003/0001104659-20-069003-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920069142/0001104659-20-069142-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920072556/0001104659-20-072556-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079248/0001104659-20-079248-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079782/0001104659-20-079782-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079783/0001104659-20-079783-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079786/0001104659-20-079786-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079787/0001104659-20-079787-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079788/0001104659-20-079788-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079789/0001104659-20-079789-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920079793/0001104659-20-079793-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920090468/0001104659-20-090468-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920090469/0001104659-20-090469-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920090470/0001104659-20-090470-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920091131/0001104659-20-091131-index.htm
2020-08-10S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1621227/000110465920092818/0001104659-20-092818-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920099887/0001104659-20-099887-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000110465920101976/0001104659-20-101976-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920115322/0001104659-20-115322-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1621227/000110465920121583/0001104659-20-121583-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005164/0001209191-20-005164-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005167/0001209191-20-005167-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005168/0001209191-20-005168-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005170/0001209191-20-005170-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005172/0001209191-20-005172-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120005173/0001209191-20-005173-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1621227/000120919120039805/0001209191-20-039805-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1621227/000142284920000007/0001422849-20-000007-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1621227/000155837020001571/0001558370-20-001571-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621227/000155837020006569/0001558370-20-006569-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621227/000155837020009555/0001558370-20-009555-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1621227/000155837020012867/0001558370-20-012867-index.htm
2020-11-04CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1621227/999999999720005282/9999999997-20-005282-index.htm

Adaptimmune Therapeutics plc (ADAP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adaptimmune Therapeutics plc (ADAP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 22%
Institutional Ownership: 8405%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-01-13HELEN KATRINA TAYTON-MARTINChief Business OfficerSell50,000.004.00200,000.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004422/0001104659-20-004422-index.htm
2020-01-13HELEN KATRINA TAYTON-MARTINChief Business OfficerSell50,000.005.00250,000.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004422/0001104659-20-004422-index.htm
2020-08-03HELEN KATRINA TAYTON-MARTINChief Business OfficerSell200,000.008.741,748,180.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920090469/0001104659-20-090469-index.htm
2020-01-13James NobleDirectorSell100,000.004.00400,000.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004419/0001104659-20-004419-index.htm
2020-01-13James NobleDirectorSell200,000.005.001,000,000.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004419/0001104659-20-004419-index.htm
2020-05-29James NobleDirectorSell500,000.009.334,666,000.000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920069142/0001104659-20-069142-index.htm
2020-06-09Lawrence M AllevaDirectorBuy12,900.001.8924,381.0012,900.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920072556/0001104659-20-072556-index.htm
2020-01-14Elliot NorryChief Medical OfficerSell911.005.134,677.711,326.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004424/0001104659-20-004424-index.htm
2020-01-06John LungerChief Patient Supply OfficerSell1,148.001.201,377.601,677.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920002082/0001104659-20-002082-index.htm
2020-01-14John LungerChief Patient Supply OfficerSell1,144.005.135,874.101,681.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004421/0001104659-20-004421-index.htm
2020-01-24Ali BehbahaniDirectorBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005167/0001209191-20-005167-index.htm
2020-01-24Anthony A. Jr. Florence10% Share HolderBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005168/0001209191-20-005168-index.htm
2020-01-24DAVID M MOTTDirectorBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005170/0001209191-20-005170-index.htm
2020-01-24FOREST BASKETT10% Share HolderBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005164/0001209191-20-005164-index.htm
2020-01-24Peter W. Sonsini10% Share HolderBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005173/0001209191-20-005173-index.htm
2020-01-24SCOTT D SANDELL10% Share HolderBuy7,500,000.000.675,000,250.0019,500,000.00https://www.sec.gov/Archives/edgar/data/1621227/000120919120005172/0001209191-20-005172-index.htm
2020-08-03Adrian RawcliffeChief Executive OfficerSell2,788.009.2525,789.003,064.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920090468/0001104659-20-090468-index.htm
2020-09-01Adrian RawcliffeChief Executive OfficerSell2,776.008.5123,637.363,076.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920101976/0001104659-20-101976-index.htm
2020-01-14Adrian RawcliffeChief Executive OfficerSell3,236.005.1316,615.893,166.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004420/0001104659-20-004420-index.htm
2020-06-29Gavin WoodChief Financial OfficerBuy33,000.001.6253,460.0033,000.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920079248/0001104659-20-079248-index.htm
2020-01-14William C JR BertrandChief Operating OfficerSell2,397.005.1312,307.883,605.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920004423/0001104659-20-004423-index.htm
2020-01-06William C JR BertrandChief Operating OfficerSell3,731.001.204,477.205,632.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920002081/0001104659-20-002081-index.htm
2020-01-06Adrian RawcliffeChief Executive OfficerSell5,900.001.207,080.005,804.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920002080/0001104659-20-002080-index.htm
2020-08-03John LungerChief Patient Supply OfficerSell4,823.009.2544,612.758,066.00https://www.sec.gov/Archives/edgar/data/1621227/000110465920090470/0001104659-20-090470-index.htm